![Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial | Breast Cancer Research | Full Text Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial | Breast Cancer Research | Full Text](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs13058-018-1050-7/MediaObjects/13058_2018_1050_Fig1_HTML.png)
Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial | Breast Cancer Research | Full Text
ESMO-BC 2022: Updated overall survival (OS) results from the first-line (1L) population in the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2? advanced breast cancer (ABC) treated with ribociclib (RIB) +
![ASCO 2021: [VIRTUAL] Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB). ASCO 2021: [VIRTUAL] Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB).](https://larvolclin.s3.us-west-2.amazonaws.com/resize_162308040295527161060be3dd24570a.png)
ASCO 2021: [VIRTUAL] Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB).
![Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial | Breast Cancer Research | Full Text Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial | Breast Cancer Research | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13058-018-1050-7/MediaObjects/13058_2018_1050_Fig1_HTML.png)
Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial | Breast Cancer Research | Full Text
![Review of the Latest Developments in Treatment of Hormone Receptor-Positive Advanced Breast Cancer - European Medical Journal Review of the Latest Developments in Treatment of Hormone Receptor-Positive Advanced Breast Cancer - European Medical Journal](https://emj.emg-health.com/wp-content/uploads/sites/2/2020/08/Figures-Tables-EL.jpg)
Review of the Latest Developments in Treatment of Hormone Receptor-Positive Advanced Breast Cancer - European Medical Journal
![Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology](https://www.annalsofoncology.org/cms/asset/d1288ff9-0c7f-4332-b902-f99345f8a27e/figs1.jpg)
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology
![Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial - The Lancet Oncology Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/asset/9ceeae9a-2bba-493e-bd30-68967999722b/gr2.jpg)
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial - The Lancet Oncology
![Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - ScienceDirect Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753421015532-gr4.jpg)
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - ScienceDirect
![Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - ScienceDirect Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753421015532-gr3.jpg)
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - ScienceDirect
Download Poster: Overall Survival with Kisqali® plus Endocrine Therapy in Patients with Advanced Breast Cancer with Visceral Metastases 6
ESMO-BC 2022: Updated overall survival (OS) results from the first-line (1L) population in the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2? advanced breast cancer (ABC) treated with ribociclib (RIB) +
![Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - ScienceDirect Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753421015532-gr1.jpg)
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - ScienceDirect
![Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - ScienceDirect Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0960977620301867-gr2a.jpg)
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - ScienceDirect
![Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer - LifeProNow LifeProNow Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer - LifeProNow LifeProNow](https://lifepronow.com/wp-content/uploads/2020/05/NOVARTIS-1-1-e1588611327141.jpg)
Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer - LifeProNow LifeProNow
![Progression-free survival. a Investigator-assessed and b Independent... | Download Scientific Diagram Progression-free survival. a Investigator-assessed and b Independent... | Download Scientific Diagram](https://www.researchgate.net/publication/330450344/figure/fig1/AS:718776249110528@1548381020006/Progression-free-survival-a-Investigator-assessed-and-b-Independent-central-review-in.jpg)
Progression-free survival. a Investigator-assessed and b Independent... | Download Scientific Diagram
![Kaplan–Meier analysis of locally assessed progression-free survival in... | Download Scientific Diagram Kaplan–Meier analysis of locally assessed progression-free survival in... | Download Scientific Diagram](https://www.researchgate.net/publication/321195924/figure/fig2/AS:961363971149836@1606218440258/Kaplan-Meier-analysis-of-locally-assessed-progression-free-survival-in-patients-with-de.gif)